CompanyGraph
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onDownstream position: depends on 11 industries, supplies 6
- ScaleMarket cap is $159.7B, higher than 95% of all stocks globally
- FinancialsAltman Z-Score 2.06: grey zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
6.14%Above 5Y avg (5.16%)
Annual Rate
USD 1.72Paid quarterly
Payout Ratio
226.3%High
Consecutive Growth
15 yrStrong track record
Paying Dividends
26 yr
Payback Period
16.1 yr
Last Ex-Dividend
Jul 24, 2026
Last Payment
Sep 1, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
159.70BUSDvs all stocks (USD)
Trailing P/E
36.63xRevenue (TTM)
63.70BUSDvs all stocks (USD)
Profit Margin
6.80%Beta
0.2800xvs all stocks
52-Week Change
13.17%vs all stocks
Forward Annual Dividend Yield
6.14%vs all stocks
Market Capitalization
159.70BUSDvs all stocks (USD)
Enterprise Value
214.92BUSDvs all stocks (USD)
Trailing P/E
36.63xForward P/E
9.87xPEG Ratio
-0.3396xPrice to Sales (TTM)
2.56xPrice to Book (MRQ)
1.91xEnterprise to Revenue
3.37xEnterprise to EBITDA
8.47xGross Margin
72.78%Profit Margin
6.80%Operating Margin
27.88%Return on Assets (TTM)
5.78%Return on Equity (TTM)
5.01%Revenue (TTM)
63.70BUSDvs all stocks (USD)
Revenue per Share (TTM)
11.19USDUpdated Aug 28, 2026Quarterly Revenue Growth
2.60%Gross Profit (TTM)
47.59BUSDvs all stocks (USD)
EBITDA (TTM)
25.49BUSDvs all stocks (USD)
Net Income (TTM)
4.34BUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
2.60%Operating Cash Flow (TTM)
13.40BUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
12.49BUSDvs all stocks (USD)
Forward Annual Dividend Rate
1.72USDUpdated Aug 28, 2026Forward Annual Dividend Yield
6.14%vs all stocks
Trailing Annual Dividend Rate
1.72USDUpdated Aug 28, 2026Trailing Annual Dividend Yield
6.14%vs all stocks
5-Year Average Dividend Yield
5.16%vs all stocks
Payout Ratio
226.32%Minority Interest (Equity)
299.00MUSDFY2025 · Dec 31, 2025Revenue
62.58BUSDFY2025 · Dec 31, 2025Cost of Goods Sold
16.07BUSDFY2025 · Dec 31, 2025Gross Profit
46.51BUSDFY2025 · Dec 31, 2025Operating Income
17.41BUSDvs all stocks (USD)
Pre-tax Income
7.52BUSDFY2025 · Dec 31, 2025Income Tax Expense
-266.00MUSDFY2025 · Dec 31, 2025Net Income
7.81BUSDFY2025 · Dec 31, 2025EBIT
10.19BUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
25.75BUSDFY2025 · Dec 31, 2025Research & Development
10.44BUSDFY2025 · Dec 31, 2025Selling, General & Administrative
13.79BUSDFY2025 · Dec 31, 2025Non-operating Interest Income
603.00MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.67BUSDFY2025 · Dec 31, 2025EPS (Basic)
1.37USDFY2025 · Dec 31, 2025EPS (Diluted)
1.36USDFY2025 · Dec 31, 2025Basic Shares Outstanding
5.68BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
5.68BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
7.79BUSDFY2025 · Dec 31, 2025Minority Interests (P&L)
-41.00MUSDFY2025 · Dec 31, 2025Operating Cash Flow
6.43BUSDFY2025 · Dec 31, 2025Free Cash Flow
3.81BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.20BUSDFY2025 · Dec 31, 2025Income Tax Paid
4.69BUSDFY2025 · Dec 31, 2025Interest Paid
2.74BUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
7.79BUSDFY2025 · Dec 31, 2025Depreciation & Amortization
6.59BUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-2.13BUSDFY2025 · Dec 31, 2025Stock-based Compensation
799.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-1.26BUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-263.00MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-469.00MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-4.62BUSDFY2025 · Dec 31, 2025Capital Expenditures
-2.63BUSDFY2025 · Dec 31, 2025Net Acquisitions
-616.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-17.32BUSDFY2025 · Dec 31, 2025Sale of Investments
19.05BUSDFY2025 · Dec 31, 2025Other Investing Activity
165.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-1.35BUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
9.68BUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-9.75BUSDFY2025 · Dec 31, 2025Net Short-term Debt Issuance
-3.00BUSDFY2025 · Dec 31, 2025Common Dividends Paid
-9.77BUSDFY2025 · Dec 31, 2025Other Financing Charges
-459.00MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-13.30BUSDFY2025 · Dec 31, 2025Shares Outstanding
5.70BSharesUpdated Aug 28, 2026Float Shares
5.69BSharesUpdated Aug 28, 2026Shares Short
149.27MSharesUpdated Aug 28, 2026Short Ratio
3.69daysvs all stocks
Short % of Shares Outstanding
2.62%vs all stocks
% Held by Insiders
0.10%vs all stocks
% Held by Institutions
69.13%vs all stocks
Total Cash (MRQ)
11.70BUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.05USDUpdated Aug 28, 2026Total Debt (MRQ)
63.48BUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7425xCurrent Ratio (MRQ)
1.27xBook Value per Share (MRQ)
14.95USDUpdated Aug 28, 2026Total Assets
208.16BUSDvs all stocks (USD)
Total Current Assets
42.90BUSDFY2025 · Dec 31, 2025Total Liabilities
121.39BUSDFY2025 · Dec 31, 2025Total Non-current Assets
165.26BUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
84.40BUSDFY2025 · Dec 31, 2025Total Current Liabilities
36.98BUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.14BUSDFY2025 · Dec 31, 2025Other Short-term Investments
12.45BUSDFY2025 · Dec 31, 2025Accounts Receivable
11.87BUSDFY2025 · Dec 31, 2025Inventory
10.65BUSDFY2025 · Dec 31, 2025Accounts Payable
5.24BUSDFY2025 · Dec 31, 2025Short-term Debt
3.15BUSDFY2025 · Dec 31, 2025Deferred Revenue
784.00MUSDFY2025 · Dec 31, 2025Other Current Liabilities
18.65BUSDFY2025 · Dec 31, 2025Long-term Debt
60.81BUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
14.73BUSDFY2025 · Dec 31, 2025Common Stock (Book)
481.00MUSDFY2025 · Dec 31, 2025Retained Earnings
114.61BUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
86.78BUSDvs all stocks (USD)
Treasury Stock
115.02BUSDFY2025 · Dec 31, 202552-Week Low
23.58USDUpdated Aug 28, 202652-Week High
28.75USDUpdated Aug 28, 202652-Week Change
13.17%vs all stocks
Beta
0.2800xvs all stocks
50-Day MA
25.40USDUpdated Aug 28, 2026200-Day MA
26.01USDUpdated Aug 28, 2026Avg 10-Day Volume
33.69MSharesUpdated Aug 28, 2026Avg 30-Day Volume
39.19MSharesUpdated Aug 28, 2026Diluted EPS (TTM)
0.7800USDUpdated Aug 28, 2026Other Income / Expense
-7.82BUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 2.26Dividend per Share: 1.72Earnings per Share: 0.78
High gross margins eroded by operating costsNotable
Gross Margin: 0.73Profit Margin: 0.07
Financial Health
Altman Z-Score 2.06: grey zoneSignificant
Altman Z-Score: 2.06
Supply Chain
Downstream position: depends on 11 industries, supplies 6Notable
Outgoing: 6.00Incoming: 11.00
High connectivity hub: 17 industry connectionsNotable
Total Connections: 17.00
Scale
Market cap is $159.7B, higher than 95% of all stocks globallySignificant
Market cap (USD): 159,704,853,963Global P95: 26,266,743,019.727
Revenue is $63.7B, higher than 95% of all stocks globallySignificant
Revenue (USD): 63,695,998,976Global P95: 15,102,391,082.578
Levered free cash flow is $12.49B, higher than 95% of all stocks globallySignificant
Levered free cash flow (USD): 12,485,624,832Global P95: 1,235,239,084.501
Companies that share the same coordination system — how they create, deliver, or capture value.
Novo Nordisk A/S
Tier 1ProductionApproval-Gated PipelineRule
Gilead Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bristol-Myers Squibb Company
Tier 1ProductionApproval-Gated PipelineRuleFlow
Vertex Pharmaceuticals Incorporated
Tier 1ProductionApproval-Gated PipelineRule
Abbott Laboratories
Tier 1ProductionApproval-Gated PipelineRuleFlow
Stryker Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Medtronic plc
Tier 1ProductionApproval-Gated PipelineRule
Amgen Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
GSK plc
Tier 1ProductionApproval-Gated PipelineRuleFlow
AstraZeneca PLC
Tier 1ProductionApproval-Gated PipelineRuleFlow